Website
News25/Ratings12
News · 26 weeks230%
2025-10-262026-04-19
Mix1090d
- SEC Filings4(40%)
- Other4(40%)
- Earnings2(20%)
Latest news
25 items- PRHaemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026BOSTON, April 1, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, May 7, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 7, 2026. The call can be accessed via teleconference at: Q4 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While n
- PRHaemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure SystemVASCADE MVP XL now approved for larger sheaths used in market-leading PFA and LAAC technologiesBOSTON, March 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval to expand the labeling for the VASCADE MVP® XL venous vascular closure system to include procedures using 10-14F inner diameter (ID) and up to 17F outer diameter (OD) procedural sheaths. With this label expansion, the VASCADE MVP XL system is approved for larger sheaths used in market-leading technologies for pulsed field ablation (PFA) and left
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Haemonetics CorporationSCHEDULE 13G/A - HAEMONETICS CORP (0000313143) (Subject)
- SECHaemonetics Corporation filed SEC Form 8-K: Regulation FD Disclosure8-K - HAEMONETICS CORP (0000313143) (Filer)
- PRHaemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS TechnologyBOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the NexSys PCS® Plasma Collection System with Persona® PLUS technology. Persona PLUS represents the next generation of Haemonetics' proprietary and patented Persona technology that tailors plasma collections to each donor for improved average plasma volume per donation. The 510(k) clearance was supported by clinical
- PRHaemonetics to Present at Raymond James 47th Annual Institutional Investors ConferenceBOSTON, Feb. 20, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026 at 10:25 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://event.summitcast.com/view/VSr8zRPFYu9jT7Rm69ptdC/DrZt2UmuNYtnB5faJBzE4N. A replay of the recorded webcast will become accessible 12 hours after the event and will be a
- SECHaemonetics Corporation filed SEC Form 8-K: Regulation FD Disclosure8-K - HAEMONETICS CORP (0000313143) (Filer)
- SECSEC Form 10-Q filed by Haemonetics Corporation10-Q - HAEMONETICS CORP (0000313143) (Filer)
- SECHaemonetics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - HAEMONETICS CORP (0000313143) (Filer)
- PRHaemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations WebsiteFinancial release and supplemental presentation accessible online BOSTON, Feb. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its third quarter fiscal year 2026, which ended December 27, 2025, are available on the Company's Investor Relations website at www.haemonetics.com. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 5, 2026. Conference Call and Webcast Information: Registration: Click here to register. Upon registra
- PROrchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnoutsVivasure Medical Limited ("Vivasure") has been a strategic holding of Orchestra BioMed since the Company's formation NEW HOPE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that it expects to receive up to $21 million in cash proceeds in connection with the acquisition of Vivasure, an Ireland-based company pioneering next-generation techn
- PRVivasure Medical Announces Acquisition by Haemonetics CorporationVivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the company has been acquired by Haemonetics Corporation (NYSE:HAE) in a transaction valued up to €185M (~$215M) on completion of certain milestones. Based in Galway, Ireland, Vivasure is focused on the development of advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology, and vascular surgery. In 2022, Vivasure Medical received a strategic investment from Haemonetics, which included an option to acquire Vivasure Medical. Earlier this year, Vivasure Medical announced the sub
- SECHaemonetics Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - HAEMONETICS CORP (0000313143) (Filer)
- PRHaemonetics Acquires Vivasure Medical LimitedBOSTON, Jan. 9, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the acquisition of Vivasure Medical Limited (Vivasure), a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure. Vivasure's PerQseal® Elite system uses a proprietary bioabsorbable patch to seal large-bore (up to 26 F) arteriotomies and venotomies from inside the vessel, offering a sutureless, fully absorbable solution for structu
- PRHaemonetics Sets Date for Publishing Third Quarter Fiscal Year 2026 Results: February 5, 2026BOSTON, Jan. 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish third quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, February 5, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 5, 2026. The call can be accessed via teleconference at: Q3 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the cal
- PRHaemonetics to Present at 44th Annual J.P. Morgan Healthcare ConferenceBOSTON, Jan. 2, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Chris Simon, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 am Pacific Time. The public may access Mr. Simon's presentation live via audio webcast at: https://jpmorgan.metameetings.net/events/healthcare26/sessions/317152-haemonetics-corp/webcast?gpu_only=true&kiosk=true The live webcast can also be accessed under the Events & Presentations section of Haemonetics' Investor Relations website. The replay
- ANALYSTHaemonetics downgraded by NeedhamNeedham downgraded Haemonetics from Buy to Hold
- ANALYSTHaemonetics downgraded by Citigroup with a new price targetCitigroup downgraded Haemonetics from Buy to Neutral and set a new price target of $88.00
- INSIDERDirector Kroll Mark W bought $98,784 worth of shares (1,400 units at $70.56), increasing direct ownership by 6% to 24,757 units (SEC Form 4)4 - HAEMONETICS CORP (0000313143) (Issuer)
- SECSEC Form 10-Q filed by Haemonetics Corporation10-Q - HAEMONETICS CORP (0000313143) (Filer)
- SECHaemonetics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - HAEMONETICS CORP (0000313143) (Filer)
- PRHaemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations WebsiteFinancial release and supplemental presentation accessible online BOSTON, Nov. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its second quarter fiscal year 2026, which ended September 27, 2025, are available on the Company's Investor Relations website at www.haemonetics.com. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 6, 2025. Conference Call and Webcast Information: Registration: Click here to register. Upon regist
- INSIDEREVP, Chief Commercial Officer Galvin Roy covered exercise/tax liability with 145 shares, decreasing direct ownership by 1% to 12,811 units (SEC Form 4)4 - HAEMONETICS CORP (0000313143) (Issuer)
- PRHaemonetics Sets Date for Publishing Second Quarter Fiscal Year 2026 Results: November 6, 2025BOSTON, Oct. 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, November 6, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 6, 2025. The call can be accessed via teleconference at: Q2 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the ca
- INSIDERSVP, Human Resources Miller Laurie A. covered exercise/tax liability with 238 shares, decreasing direct ownership by 0.82% to 28,925 units (SEC Form 4)4 - HAEMONETICS CORP (0000313143) (Issuer)